Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05780034 · ClinicalTrials.gov registry record · Phase 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
A Phase 1 study of Relapsed/Refractory B-cell Malignancies, sponsored by Accutar Biotechnology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT05780034 is a Phase 1 study of Relapsed/Refractory B-cell Malignancies that is actively recruiting participants, run by Accutar Biotechnology. The registered enrollment target is 60 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT05780034, a Phase 1 study of Relapsed/Refractory B-cell Malignancies, is actively recruiting participants, sponsored by Accutar Biotechnology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676
Conditions Studied
Interventions
- DRUG AC676
Study Locations (9)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute - Columbus
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Florida Cancer Specialists - Sarasota
North Carolina
- University of North Carolina - Chapel Hill
Oregon
- Oregon Health & Science University - Portland
Tennessee
- Tennessee Oncology - Nashville
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05780034
The ClinicalTrials.gov registry entry for NCT05780034 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accutar Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory B-cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AC676 is the first listed.
NCT05780034 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Ohio, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT05780034 about?
NCT05780034 is a clinical study titled "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies". This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokin...
What is the current status of trial NCT05780034?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-06-20. Estimated completion is 2026-05-31.
What conditions does trial NCT05780034 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-cell Malignancies.
What interventions are being tested in trial NCT05780034?
The interventions under investigation include: AC676 (DRUG).
Who is sponsoring clinical trial NCT05780034?
This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05780034 being conducted?
This trial has 9 study locations across Colorado, Florida, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.